Education
About Us
Working with TipRanks
Follow Us
Mckesson Corp. (MCK)
NYSE:MCK
Earnings Data
Report Date
May 13, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
11.56Last Year’s EPS
10.12Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and financial picture: strong double-digit top-line and EPS growth, raised full-year guidance, robust segment performance (notably oncology, specialty distribution and RxTS), solid cash generation, active buybacks, and successful acquisition integrations. Challenges are relatively contained: medical-surgical profitability pressure, quarter-to-quarter variability driven by seasonality/launch timing, and some uncertainty around GLP-1 channel evolution and near-term technology investment costs. Overall, the positives (growth, margin expansion, cash flow, strategic progress) materially outweigh the noted headwinds.Company Guidance
Record Quarterly Revenue and Strong EPS
Consolidated revenues increased 11% year-over-year to $106.2 billion. Third quarter diluted EPS increased 16% to $9.34, driven by operational performance and acquisitions.
Raised Full-Year Guidance
Full-year adjusted EPS guidance raised to $38.80–$39.20 (17–19% YoY growth). Company also set revenue growth guidance of 12–16% and operating profit growth guidance of 13–17% for fiscal 2026.
Oncology & Multispecialty: Rapid Growth and Accretion from Acquisitions
Oncology and multispecialty revenues grew 37% year-over-year to $13.0 billion; operating profit rose 57% to $366 million. Acquisitions (Prism and Core Ventures) contributed ~13% to Q3 segment revenue growth and are expected to contribute ~30–34% to fiscal 2026 segment operating profit growth.
North American Pharmaceutical Distribution Momentum
North American Pharmaceutical revenues were $88.3 billion, up 9% YoY, supported by higher prescription volumes, specialty distribution strength, and health system volumes. Segment operating profit increased 6% to $872 million.
Substantial GLP-1 Distribution Growth
GLP-1 distribution revenues were $14.0 billion in the quarter, up $3.0 billion (26% YoY) with sequential growth of 7%.
Prescription Technology Solutions (RxTS) Performance
RxTS revenues increased 9% to $1.5 billion and operating profit rose 18% to $277 million, driven by demand for access, affordability, and prior authorization services and new program additions (50 new programs across 43 brands).
Profitability, Efficiency and Cash Generation
Gross profit increased 10% to $3.7 billion; operating profit rose 13% to $1.7 billion. Operating expense improvement of 138 basis points as a percentage of gross profit. Q3 free cash flow was $1.1 billion; trailing twelve months free cash flow was $9.6 billion. Ended quarter with $3.0 billion in cash and returned $781 million to shareholders (including $680 million in repurchases).
Balance Sheet Strength and Capital Return Plan
Company plans ~ $2.0 billion in share repurchases for fiscal 2026, expects free cash flow of $4.4–$4.8 billion, and maintains an investment-grade balance sheet. Return on invested capital improved by ~1,900 basis points since fiscal 2020, now exceeding 30%.
Progress on Portfolio Actions and Separation
Completed divestiture of Norway (final exit from Europe) and achieved transition service agreements for the medical-surgical separation. Tracking toward an IPO of the medical-surgical business by H2 calendar 2027 (subject to market/regulatory conditions).
Technology & Automation Wins
AI and automation initiatives improved productivity (each FTE supporting ~120 more patients in annual verification season), DSCSA AI chat tool prevented 75% of inquiries from escalating, and Canadian contact-center pilots approaching ~100% service accuracy.
MCK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MCK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | $822.00 | $957.80 | +16.52% |
Nov 05, 2025 | $843.47 | $857.81 | +1.70% |
Aug 06, 2025 | $702.26 | $661.84 | -5.76% |
May 08, 2025 | $688.10 | $691.30 | +0.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mckesson Corp. (MCK) report earnings?
Mckesson Corp. (MCK) is schdueled to report earning on May 13, 2026, Before Open (Confirmed).
What is Mckesson Corp. (MCK) earnings time?
Mckesson Corp. (MCK) earnings time is at May 13, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MCK EPS forecast?
MCK EPS forecast for the fiscal quarter 2026 (Q4) is 11.56.